Get the Stockscreener App
137.94
5.70%
7.44
After Hours:
138.22
0.28
+0.20%
Sarepta Therapeutics Inc stock is traded at $137.94, with a volume of 2.90M.
It is up +5.70% in the last 24 hours and up +5.19% over the past month.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
See More
Previous Close:
$130.50
Open:
$130.94
24h Volume:
2.90M
Relative Volume:
3.11
Market Cap:
$12.99B
Revenue:
$1.64B
Net Income/Loss:
$121.85M
P/E Ratio:
-17.62
EPS:
-7.83
Net Cash Flow:
$-480.40M
1W Performance:
+24.43%
1M Performance:
+5.19%
6M Performance:
+11.73%
1Y Performance:
+67.04%
1-Day Range:
$130.00
$138.10
1-Week Range:
$109.03
$138.10
52-Week Range:
$78.67
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
137.94 | 12.99B | 1.64B | 121.85M | -480.40M | -7.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Arrowhead: The Sarepta Partnership Validates RNAi Platform And Reduces Risk (NASDAQ:ARWR) - Seeking Alpha
Arrowhead, Sarepta Stocks Rise Despite Price-Target Cuts Post $1B Licensing Deal: Retail Buzz Strong - MSN
SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies - Yahoo Finance
Sarepta rebuilds drug pipeline with Arrowhead deal - BioPharma Dive
Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 42.11%: Read This Before Placing a Bet - Yahoo Finance
Needham & Company LLC Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $202.00 - MarketBeat
Rx Rundown: Roche, Sarepta Therapeutics, Merck and more - MM+M Online
Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments - Yahoo Finance
Arrowhead to get $825M in Sarepta licensing pact, appoints Sarepta CEO to board - Yahoo Finance
What is HC Wainwright's Forecast for SRPT FY2024 Earnings? - MarketBeat
Arrowhead and Sarepta link for rare genetic disease treatments - Pharmaceutical Technology
Arrowhead climbs after licensing deal with Sarepta - MSN
Sarepta Therapeutics Breaks Above 200-Day Moving AverageBullish for SRPT - Nasdaq
Innovators in Healthcare and Life Sciences AwardsColumbus Business First - The Business Journals
Arrowhead, Sarepta Launch On A Whopping $11.38 Billion Deal - Investor's Business Daily
U.S. Markets Moved Upward Tuesday; Sarepta Therapeutics Climbed Highest - Barron's
Arrowhead Pharma, Sarepta TX ink new gene therapy deal - Yahoo Finance
Sarepta Therapeutics GC Departs Role As Deputy Steps Up - Law360
Sarepta CEO looks beyond Duchenne in $1B+ deal - The Business Journals
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On? - Benzinga
More than $11 billion at stake in Arrowhead and Sarepta deal - The Pharma Letter
Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal - Yahoo! Voices
Sarepta Aims Up to $10B at Arrowhead to Diversify Pipeline With RNA Drugs - BioSpace
Arrowhead stock soars on $825M Sarepta Therapeutics deal - Investing.com
Arrowhead stock soars on $825M Sarepta Therapeutics deal By Investing.com - Investing.com UK
Arrowhead stock up on Sarepta licensing deal (ARWR:NASDAQ) - Seeking Alpha
Sarepta Therapeutics Announces Leadership Change and Equity Deal - TipRanks
Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs - BioSpace
Sarepta Therapeutics, Arrowhead Pharmaceuticals Ink Collaboration, Licensing Deal - MarketWatch
Sarepta inks global licensing deal with Arrowhead - Investing.com
SRPTSarepta Therapeutics,, Inc. Latest Stock News & Market Updates - StockTitan
Arrowhead Pharma Lands $825M Mega-Deal with Sarepta, Up to $10B in Milestones | SRPT Stock News - StockTitan
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga
HC Wainwright Initiates Coverage on Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
Analyst Expectations For Sarepta Therapeutics's Future - Benzinga
Larson Financial Group LLC Increases Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Eagle Asset Management Inc. - MarketBeat
High Growth Tech Stocks to Watch in November 2024 - Simply Wall St
Connor Clark & Lunn Investment Management Ltd. Increases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Victory Capital Management Inc. Has $8.28 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program - MSN
S&P 500 Futures Climb in Premarket Trading; Target, Fabrinet Lag - Barron's
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday - MSN
Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
Sarepta upgraded at Cantor on pipeline, growth potential - MSN
Sarepta Therapeutics (NASDAQ:SRPT) Lowered to "Hold" Rating by StockNews.com - MarketBeat
Braun Stacey Associates Inc. Grows Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Thrivent Financial for Lutherans Trims Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
FDA endorses speedy approval path for Regenxbio Duchenne gene therapy - Yahoo Finance
Cantor Fitzgerald Upgrades Sarepta Therapeutics (SRPT) - MSN
Aigen Investment Management LP Lowers Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):